Skip to content

Improving Metabolic Health in Patients With Diastolic Dysfunction

Reduction of Cardiac Steatosis and Improvement of Diastolic Function by Modulating Metabolic Health in Obese Individuals

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03448185
Acronym
MTG
Enrollment
80
Registered
2018-02-27
Start date
2015-06-01
Completion date
2019-07-01
Last updated
2023-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Diastolic, Metabolic Syndrome, Obesity

Brief summary

The purpose of this study is to determine whether 1 year of supervised exercise training in obese individuals at high risk for developing HF, incorporating high intensity interval training (HIIT) two to three times per week in conjunction with daily oral administration of omega-3 poly-unsaturated fatty acids will lead to reduction in visceral adiposity, regression of myocardial triglyceride levels and improvements in cardiac diastolic and vascular function.

Detailed description

The global objective of this project is to test novel strategies to prevent obesity related abnormalities in diastolic function that may progress to heart failure with preserved ejection fraction (HFpEF). These include: a) identifying high risk individuals by using population derived imaging and blood biomarkers; and b) implementing novel exercise training and nutri-ceutical strategies in obese middle aged individuals with high amounts of visceral fat, an important risk factor in the development of heart failure and adverse cardiac remodeling. Prior work has demonstrated that: a) high levels of myocardial triglyceride content are associated with a smaller and less distensible left ventricle with reduced tissue relaxation rates compared to those with low levels and b) low fitness and high body mass index were the strongest predictors of elevated myocardial content. The consequences of excess visceral adiposity (intra- and retro-peritoneal adipose tissue) on cardiac remodeling suggest individuals with high visceral fat content and low fitness are at particularly high risk for heart failure. The primary objective of this project is therefore to identify high risk, sedentary, middle aged obese individuals with high visceral fat levels, and initiate an exercise program in conjunction with omega-3 fatty acid supplementation designed to reduce visceral adiposity and regress myocardial triglyceride accumulation. Findings from this aim would have enormous public health significance and establish a novel, practical exercise training program and nutria-ceutical strategy to reverse obesity related cardiovascular remodeling. Hypothesis: High aerobic exercise training in conjunction with daily omega-3 supplementation will reduce visceral myocardial triglyceride accumulation by reducing visceral adiposity. A reduction of myocardial fat will lead to improved LV structure and diastolic function by an approach that is not necessarily predicated on weight loss. Specific Aim: To test our hypothesis that reduction in myocardial triglyceride content will improve markers of diastolic function, we have designed a randomized, double blind, placebo controlled trial. We will study four groups of previously sedentary obese middle aged subjects at high risk for development of HF for one year with the following interventions: A) sedentary controls taking placebo; B) sedentary subjects taking omega-3 fatty acids; C) subjects undergoing high intensity aerobic exercise training while on placebo and D) subjects undergoing high intensity aerobic exercise training while taking omega-3 fatty acids. Subjects will be categorized as high risk and enrolled on the basis of elevated serum biomarkers (cTnT) and high visceral fat content (\>2.5 kg). We will perform comprehensive non-invasive assessments of cardiovascular structure and systolic/diastolic function before and after 1 year of an exercise intervention involving high intensity intervals and omega-3 administration. We anticipate the combination of high intensity aerobic exercise in conjunction with high dose omega-3 supplementation will reduce visceral adiposity, decrease myocardial triglyceride content and improve markers of diastolic and vascular function.

Interventions

BEHAVIORALHigh intensity exercise

Subjects will be randomized to the exercise groups will undergo 1 year aerobic exercise training comprised of high intensity exercise sessions 2-3 days per week. Sessions will be supervised remotely via heart rate monitors.

DIETARY_SUPPLEMENTOmega-3 fish oil

Subjects randomized to omega-3 fatty acids will take 2 grams total of omega-3 per day for 1 year.

BEHAVIORALYoga

Subjects randomized to yoga will undergo yoga training as a control to those randomized to high intensity aerobic exercise.

DIETARY_SUPPLEMENTolive oil capsules

Subjects randomized to receive olive oil placebo will take 1 gram total of olive oil capsule per day.

Sponsors

University of Texas Southwestern Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

Subjects and investigative team (except for statistician) are blinded to omega-3 vs olive oil placebo. Subjects and investigators are aware of exercise modality. Outcomes assessors are blinded to all aspects of subject randomization.

Intervention model description

2x2 factorial design. Subjects are randomized to aerobic exercise or yoga as well as high dose omega-3 fatty acids or olive oil placebo.

Eligibility

Sex/Gender
ALL
Age
40 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

1. ejection fraction \>0.50 2. \>2.0 kg visceral fat (intra- and retro-peritoneal adipose tissue) 3. either a high sensitivity troponin (\>0.6pg/ml), or NTBNP (\>40 ng/ml) 4. age range 40 -60 5. BMI range 30 - 50 kg/m2

Exclusion criteria

1. age \< 40 or \> 60 2. body mass index \> 50, \< 30 kg/m2 3. history of insulin dependent diabetes, heart failure, myocarditis, restrictive cardiomyopathy, permanent/persistent atrial fibrillation, severe chronic obstructive pulmonary disease, unstable coronary artery disease or recent (\<12 month) acute coronary syndrome, cerebrovascular disease as evidenced by prior transient ischemic attack or stroke and active/recent tobacco use (quit \< 5 years). 4. Female patients will be excluded if they are pregnant or plan to become pregnant (expected rare occurrence in the selected age range of 40 - 60). 5. Patients will be excluded if they are taking non-statin lipid lowering agents (fibrates, niacin, or fish oils) 5. Contra-indications to MRI

Design outcomes

Primary

MeasureTime frameDescription
Change From Baseline at 1 Year in Myocardial Lipid ContentBaseline, 1 yearMyocardial triglyceride (lipid) content will be measured using cardiac nuclear magnetic resonance spectroscopy. We quantified the total myocardial triglyceride (TG) resonance from water-suppressed spectra. Myocardial TG content relative to water (%) as well as relative amounts of myocardial TG was calculated from the available data.

Secondary

MeasureTime frameDescription
Change From Baseline at 1 Year in Peak Volume of Oxygen (VO2)Baseline,1 yearChange in peak VO2 (normalized for body weight those who completed the study). Peak VO2 is a measure how well the heart and lungs are working during exercise.
Change From Baseline at 1 Year in Markers of Arterial StiffnessBaseline, 1 yearChanges in arterial stiffness is measured using pulse-wave velocity (PWV) to look at intervention effects from baseline to 1 year in the control and treatment groups.
Change From Baseline at 1 Year in Left Ventricular MassBaseline, 1 yearChange in left ventricular mass is measured by cardiac MRI to look at intervention effects from baseline to 1 year in the control and treatment groups.

Countries

United States

Participant flow

Participants by arm

ArmCount
Control
Subjects randomized to control group will receive olive oil placebo capsules and yoga intervention for 1 year. Yoga: Subjects randomized to yoga will undergo yoga training as a control to those randomized to high intensity aerobic exercise. olive oil capsules: Subjects randomized to receive olive oil placebo will take 1 gram total of olive oil capsule per day.
16
Exercise and Omega-3 Fatty Acids
Subjects will receive high dose omega-3 fatty acids as well as aerobic exercise intervention for 1 year. High intensity exercise: Subjects will be randomized to the exercise groups will undergo 1 year aerobic exercise training comprised of high intensity exercise sessions 2-3 days per week. Sessions will be supervised remotely via heart rate monitors. Omega-3 fish oil: Subjects randomized to omega-3 fatty acids will take 2 grams total of omega-3 per day for 1 year.
24
Yoga and Omega-3 Fatty Acids
Subjects will receive high dose omega-3 fatty acids as well as yoga intervention for 1 year. Omega-3 fish oil: Subjects randomized to omega-3 fatty acids will take 2 grams total of omega-3 per day for 1 year. Yoga: Subjects randomized to yoga will undergo yoga training as a control to those randomized to high intensity aerobic exercise.
18
Exercise Control
Subjects will receive olive oil placebo as well as aerobic exercise intervention for 1 year. High intensity exercise: Subjects will be randomized to the exercise groups will undergo 1 year aerobic exercise training comprised of high intensity exercise sessions 2-3 days per week. Sessions will be supervised remotely via heart rate monitors. olive oil capsules: Subjects randomized to receive olive oil placebo will take 1 gram total of olive oil capsule per day.
22
Total80

Baseline characteristics

CharacteristicControlTotalExercise ControlYoga and Omega-3 Fatty AcidsExercise and Omega-3 Fatty Acids
Age, Continuous49 years
STANDARD_DEVIATION 6
49 years
STANDARD_DEVIATION 6
50 years
STANDARD_DEVIATION 6
47 years
STANDARD_DEVIATION 9
50 years
STANDARD_DEVIATION 6
BMI36.7 kg/m^2
STANDARD_DEVIATION 5.2
38.9 kg/m^2
STANDARD_DEVIATION 5.7
36.7 kg/m^2
STANDARD_DEVIATION 5
40.5 kg/m^2
STANDARD_DEVIATION 6.5
36.7 kg/m^2
STANDARD_DEVIATION 5.3
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants2 Participants0 Participants0 Participants1 Participants
Race (NIH/OMB)
Asian
0 Participants2 Participants1 Participants1 Participants0 Participants
Race (NIH/OMB)
Black or African American
3 Participants17 Participants3 Participants6 Participants5 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
12 Participants59 Participants18 Participants11 Participants18 Participants
Sex: Female, Male
Female
11 Participants48 Participants12 Participants10 Participants15 Participants
Sex: Female, Male
Male
5 Participants32 Participants10 Participants8 Participants9 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 130 / 130 / 140 / 16
other
Total, other adverse events
0 / 130 / 130 / 140 / 16
serious
Total, serious adverse events
0 / 130 / 130 / 140 / 16

Outcome results

Primary

Change From Baseline at 1 Year in Myocardial Lipid Content

Myocardial triglyceride (lipid) content will be measured using cardiac nuclear magnetic resonance spectroscopy. We quantified the total myocardial triglyceride (TG) resonance from water-suppressed spectra. Myocardial TG content relative to water (%) as well as relative amounts of myocardial TG was calculated from the available data.

Time frame: Baseline, 1 year

ArmMeasureValue (MEAN)Dispersion
ControlChange From Baseline at 1 Year in Myocardial Lipid Content-0.16 %fat/waterStandard Deviation 1.1
Exercise and Omega-3 Fatty AcidsChange From Baseline at 1 Year in Myocardial Lipid Content-0.18 %fat/waterStandard Deviation 0.59
Yoga and Omega-3 Fatty AcidsChange From Baseline at 1 Year in Myocardial Lipid Content-0.53 %fat/waterStandard Deviation 0.66
Exercise ControlChange From Baseline at 1 Year in Myocardial Lipid Content-0.19 %fat/waterStandard Deviation 0.42
Secondary

Change From Baseline at 1 Year in Left Ventricular Mass

Change in left ventricular mass is measured by cardiac MRI to look at intervention effects from baseline to 1 year in the control and treatment groups.

Time frame: Baseline, 1 year

ArmMeasureValue (MEAN)Dispersion
ControlChange From Baseline at 1 Year in Left Ventricular Mass0.2 gramsStandard Deviation 7.7
Exercise and Omega-3 Fatty AcidsChange From Baseline at 1 Year in Left Ventricular Mass7.2 gramsStandard Deviation 6.6
Yoga and Omega-3 Fatty AcidsChange From Baseline at 1 Year in Left Ventricular Mass-5.8 gramsStandard Deviation 10.4
Exercise ControlChange From Baseline at 1 Year in Left Ventricular Mass6.0 gramsStandard Deviation 10
Secondary

Change From Baseline at 1 Year in Markers of Arterial Stiffness

Changes in arterial stiffness is measured using pulse-wave velocity (PWV) to look at intervention effects from baseline to 1 year in the control and treatment groups.

Time frame: Baseline, 1 year

ArmMeasureValue (MEAN)Dispersion
ControlChange From Baseline at 1 Year in Markers of Arterial Stiffness-15 cm/sStandard Deviation 107
Exercise and Omega-3 Fatty AcidsChange From Baseline at 1 Year in Markers of Arterial Stiffness-16 cm/sStandard Deviation 80
Yoga and Omega-3 Fatty AcidsChange From Baseline at 1 Year in Markers of Arterial Stiffness32 cm/sStandard Deviation 141
Exercise ControlChange From Baseline at 1 Year in Markers of Arterial Stiffness-7 cm/sStandard Deviation 104
Secondary

Change From Baseline at 1 Year in Peak Volume of Oxygen (VO2)

Change in peak VO2 (normalized for body weight those who completed the study). Peak VO2 is a measure how well the heart and lungs are working during exercise.

Time frame: Baseline,1 year

ArmMeasureValue (MEAN)Dispersion
ControlChange From Baseline at 1 Year in Peak Volume of Oxygen (VO2)0.21 ml/kg/minStandard Deviation 1.59
Exercise and Omega-3 Fatty AcidsChange From Baseline at 1 Year in Peak Volume of Oxygen (VO2)4.39 ml/kg/minStandard Deviation 2.48
Yoga and Omega-3 Fatty AcidsChange From Baseline at 1 Year in Peak Volume of Oxygen (VO2)-0.03 ml/kg/minStandard Deviation 1.84
Exercise ControlChange From Baseline at 1 Year in Peak Volume of Oxygen (VO2)4.53 ml/kg/minStandard Deviation 2.65

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026